China Tobacco Hong Kong's 2022 Annual Report

Mar.13.2023
China Tobacco Hong Kong's 2022 Annual Report
China Tobacco Hong Kong's net profit falls 46.66% while new tobacco business sees 10% growth in 2022 fiscal year.

On March 9th, China Tobacco International HK Co. Ltd. released its annual report for the 2022 fiscal year on the Hong Kong stock exchange. According to the report, the company's net profit in 2022 decreased by 46.66% compared to the previous year. However, its new tobacco business saw a 10% increase in sales, and the company's operations in Brazil saw impressive growth.


China Tobacco Hong Kong reported a total operating income of HKD 8.324 billion (approximately RMB 7.3 billion) for the fiscal year 2022, showing a year-on-year growth of 3.23%. However, the net profit attributable to the parent company was HKD 375 million (approximately RMB 330 million), marking a significant decline of 46.66% from the previous year. The basic earnings per share were HKD 0.54.


China Tobacco Hong Kong has explained that the decline in performance is mainly due to weak sales in local cigarette markets in Southeast Asia, caused by increased tobacco taxes and the impact of the pandemic, as well as a weakened demand for tobacco leaves from customers. Additionally, there has been a reduction in suitable tobacco resources available for exportation from China.


Image source: Hong Kong Stock Exchange.


CNTC Hong Kong's new tobacco product exports increased by 47,620 thousand units YoY, accounting for a growth rate of 10%, with total export quantities being 502,390 thousand units. Revenue also increased by HKD 86 million (approximately CNY 75.3 million), resulting in a total revenue of HKD 110 million (approximately CNY 96.33 million), reflecting an 8% increase YoY. However, gross profit decreased by HKD 3.2 million (approximately CNY 2.8 million), representing an 8% decline YoY.


China Tobacco Hong Kong has attributed the growth in sales and revenue of its new tobacco products to its expansion into new markets such as the Middle East, Western Europe, and Eastern Europe. The company has also increased efforts to upgrade its products in response to changing market demands. However, the decrease in profit margin is due to increased investment in marketing resources aimed at gaining more market share.


It is worth mentioning that according to China National Tobacco Corporation Hong Kong's 2022 annual report, its business in Brazil has also grown significantly. Its non-wholly owned subsidiary, CBT, under China National Tobacco Corporation Brazil, exported 29,247 tons of tobacco products to regions outside of China, a year-on-year increase of 33%; revenue was 543 million yuan, a year-on-year increase of 73%; and gross profit was 123 million yuan, a year-on-year increase of 139%.


According to an announcement, China National Tobacco Corporation Hong Kong (CNTC Hong Kong) plans to seize the opportunity presented by the adjustment of China's domestic epidemic prevention policies to continue implementing a dual-wheel development model based on both outward and inward growth. The company will focus on promoting the development of new tobacco product export business and a recovery of cigarette export business.


Reference:


International Chinese cigarette company, limited (Hong Kong) has released their annual report as of December 31, 2022.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Isle of Wight councillors raise concerns about youth vaping; one says it may be seen “akin to asbestos”
Isle of Wight councillors raise concerns about youth vaping; one says it may be seen “akin to asbestos”
Concerns about the effects of vaping on young people and public health were raised at County Hall, the report said, with Cllr Chris Jarman saying it may one day be viewed as “akin to asbestos.” Jarman cited NHS-related research and a case highlighted by Hull University Teaching Hospitals NHS Trust: a 15-year-old admitted with chest pain and breathing difficulty who reported cannabis use and vaping about 500 puffs per day and was diagnosed via CT with “air leak syndrome.”
Feb.27 by 2FIRSTS.ai
Product | Refillable up to 30 mL in total and claimed 60,000 puffs: MASKKING launches open-system UCEE MAX
Product | Refillable up to 30 mL in total and claimed 60,000 puffs: MASKKING launches open-system UCEE MAX
E-cigarette brand MASKKING has recently listed its new UCEE MAX on its official website. According to the website, the device features an open, refillable design with a stated 10 mL e-liquid capacity, supports three refills, and claims a total of 60,000 puffs.
Mar.02 by 2FIRSTS.ai
Singapore hikes vape penalties: users face up to S$10,000; importers up to 9 years
Singapore hikes vape penalties: users face up to S$10,000; importers up to 9 years
Singapore Parliament passes law to significantly increase penalties for e-cigarette possession, use, import, and sale, effective May 1.
Mar.09 by 2FIRSTS.ai
Poland to Discuss Revised E-Cigarette Definitions With Focus on Induction Technology
Poland to Discuss Revised E-Cigarette Definitions With Focus on Induction Technology
According to the agenda published by Poland’s Council of Ministers on Monday, the government is set to consider a draft amendment to the Excise Tax Act on Tuesday.
Apr.14 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
New Mexico Attorney General Files Lawsuit Over Sales of Flavored Disposable E-Cigarettes
New Mexico Attorney General Files Lawsuit Over Sales of Flavored Disposable E-Cigarettes
The New Mexico Department of Justice announced that it has filed a lawsuit against major convenience store chains and distributors, alleging that they sold flavored disposable e-cigarettes and contributed to youth nicotine addiction across the state.
Apr.01 by 2FIRSTS.ai